Highlights

  • Praxis disclosed a prespecified intent-to-treat tipping point analysis that did not tip and filed its Form 10-Q on November 9.
  • PDUFA target action dates are December 27, 2026 for relutrigine and January 29, 2027 for ulixacaltamide.
  • Net loss was $94,234 thousand, or $3.23 per share, for the quarter ended September 30, 2026, compared with $73,934 thousand.
  • Cash, cash equivalents and marketable securities were $1.3 billion, which the company expects to fund operations into 2028.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) shares were trading at USD 305.11 on November 17, 2026, down 1.66%, with a relative Volume at time of 2.29. The precision neuroscience biopharmaceutical company filed its Form 10-Q for the quarter ended September 30, 2026, on November 9 and disclosed a prespecified intent-to-treat tipping point analysis that did not tip.

Praxis is a Delaware corporation with principal executive offices in Boston, Massachusetts. It develops therapies for central nervous system disorders, applying insights from genetic epilepsies through two platforms: Cerebrum, a small molecule platform, and Solidus, an antisense oligonucleotide platform. Its late-stage candidates are ulixacaltamide, relutrigine, vormatrigine and elsunersen. The company was incorporated in 2015, uses a virtual Research and Development model, has not generated Revenue from product sales and reports on a December 31 fiscal year. As of November 4, 2026, 27,951,553 shares of common stock were outstanding.

Tipping Point Analysis and FDA Dates

Praxis disclosed a prespecified intent-to-treat tipping point analysis that did not tip. The ulixacaltamide New Drug Application for essential tremor was accepted for review with a PDUFA target action date of January 29, 2027. The company said the late-cycle meeting was completed, key discussions centered on labeling topics, and the FDA confirmed no advisory committee meeting is planned.

For relutrigine, in SCN2A and SCN8A developmental and epileptic encephalopathies, the FDA extended the review period by three months in June 2026, setting an updated PDUFA action date of December 27, 2026. The company said key late-cycle discussions centered on open questions and recent FDA information requests. The FDA completed its Bioresearch Monitoring inspection of both applications, and no Form 483 was issued.

Third Quarter Results

Praxis has not generated revenue from product sales. For the quarter ended September 30, 2026, research and development expenses were $64,205 thousand, compared with $65,797 thousand, and general and administrative expenses were $42,709 thousand, compared with $12,562 thousand. The company attributed the general and administrative increase primarily to higher personnel costs and commercial spend as it prepares for potential launches of ulixacaltamide and relutrigine.

Loss from operations was $106,914 thousand, compared with $78,359 thousand, and other income, net was $12,680 thousand, compared with $4,425 thousand. The net loss was $94,234 thousand, or $3.23 per share, compared with $73,934 thousand, or $3.36 per share. For the nine months, the net loss was $270,515 thousand, or $9.31 per share.

Cash, Funding and Capital

At September 30, 2026, cash and cash equivalents were $361,851 thousand, marketable securities were $383,472 thousand and long-term marketable securities were $540,703 thousand. Total liabilities were $52,498 thousand and stockholders' Equity was $1,259,575 thousand. The accumulated Deficit was $1.4 billion.

Net cash used in Operating Activities for the nine months was $245,432 thousand, compared with $172,743 thousand. Net cash provided by financing activities was $614,932 thousand, consisting primarily of net proceeds from a January 2026 offering of 2,543,800 shares at $260.00 per share. The company said it has no committed external source of funds and may need to obtain additional funds, and that Equity Financing would dilute stockholders.

Pipeline and Expected Milestones

The company said topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies are anticipated in the fourth quarter of 2026. For vormatrigine, the primary endpoint was not met in the POWER1 study in June 2026, POWER2 has restarted, and the company expects to initiate POWER3 in 2027.

For elsunersen, the FDA granted Breakthrough Therapy Designation in June 2026, and the company expects topline results from the EMBRAVE3 study in 2027. Praxis said it expects its expenses to be maintained or increase as it prepares for potential commercialization.